Order Article Reprints

Janku F, Choong GM, Opyrchal M, Dowlati A, Hierro C, Rodon J, Wicki A, Forster MD, Blagden SP, Yin J, et al. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers. 2024; 16(6):1137. https://doi.org/10.3390/cancers16061137

Janku, Filip, Grace M. Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D. Forster, Sarah P. Blagden, Jun Yin, and et al. 2024. "A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors" Cancers 16, no. 6: 1137. https://doi.org/10.3390/cancers16061137

Janku, F., Choong, G. M., Opyrchal, M., Dowlati, A., Hierro, C., Rodon, J., Wicki, A., Forster, M. D., Blagden, S. P., Yin, J., Reid, J. M., Muller, H., Cmiljanovic, N., Cmiljanovic, V., & Adjei, A. A. (2024). A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers, 16(6), 1137. https://doi.org/10.3390/cancers16061137